CDA | Evidence Driven
CDA | Evidence Driven

Lenvima for Differentiated Thyroid Cancer – Details

Details

Files
Generic Name:
Lenvatinib
Project Status:
Complete
Therapeutic Area:
Differentiated Thyroid Cancer
Manufacturer:
Eisai Limited
Brand Name:
Lenvima
Project Line:
Reimbursement Review
Project Number:
PC0080-000
NOC Status at Filing:
Post NOC
Performance Metric:
Achieved
Strength:
4mg and 10mg Capsules
Tumour Type:
Endocrine
Indications:
Differentiated Thyroid Cancer
Funding Request:
For the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory DTC
Sponsor:
Eisai Limited
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Requested and Granted
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
pERC Meeting:
Final Recommendation Issued:

Files

Provincial Funding Summary View PDF
Lenvatinib (Lenvima) DTC – pERC Final Recommendation Final Recommendation September 20, 2016 View PDF
Lenvatinib (Lenvima) Differentiated Thyroid Cancer – Final Clinical Guidance Report Guidance Reports September 20, 2016 View PDF
Lenvatinib (Lenvima) Differentiated Thyroid Cancer – Final Economic Guidance Report Guidance Reports September 20, 2016 View PDF
Lenvatinib (Lenvima) Differentiated Thyroid Cancer – pERC Initial Recommendation Initial Recommendation September 1, 2016 View PDF
Lenvatinib (Lenvima) DTC - PAG Feedback on Initial Recommendation Feedback September 20, 2016 View PDF
Lenvatinib (Lenvima) DTC - Manufacturer Feedback on Initial Recommendation Feedback September 20, 2016 View PDF
Lenvatinib (Lenvima) DTC - Patient Advocacy Group COI Declarations COI Declarations September 20, 2016 View PDF
Lenvatinib (Lenvima) DTC - Clinicians COI Declarations COI Declarations September 20, 2016 View PDF

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.

Last Updated : October 5, 2016